Joseph Roswarski

2PUBLICATIONS
1CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Jan 11, 2019
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.

Joseph Roswarski, Mark Roschewski, Christopher Melani

|Oct 17, 2017
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Joseph Roswarski, Mark Roschewski, Andrea Lucas

Pageof 1

Frequent Collaborators

1 joint publications

Thomas A Waldmann